Education
About Us
Working with TipRanks
Follow Us
BridgeBio Pharma Inc (BBIO)
NASDAQ:BBIO
BBIO Analyst Ratings
Strong Buy
15 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
BBIO Stock 12 Month Forecast
Average Price Target
$58.81
▲(59.20% Upside)
| Highest Price Target$95.00 | Average Price Target$58.81 | Lowest Price Target$37.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Mizuho Securities
Reiterated
05/02/25
Piper Sandler
Reiterated
04/30/25
Cantor Fitzgerald
Reiterated
04/29/25
Bank of America Securities
Reiterated
04/29/25
Leerink Partners
Reiterated
04/29/25
BMO Capital
$37
Hold
0.16%
Upside
Reiterated
04/29/25
Cautious Outlook for BridgeBio Pharma Amid Competitive Pressures and Market Uncertainties
H.C. Wainwright
$49→$53
Buy
43.48%
Upside
Reiterated
04/15/25
BridgeBio price target raised to $53 from $49 at H.C. WainwrightBridgeBio price target raised to $53 from $49 at H.C. Wainwright
Raymond James
$57
Buy
54.30%
Upside
Reiterated
04/01/25
Raymond James reiterates Outperform Rating on BridgeBio Pharma (BBIO)Raymond James analyst Danielle Brill reiterated an Outperform rating and $57.00 price target on BridgeBio Pharma (NASDAQ: BBIO).
Josh Smith CFA
Not Ranked
Redburn Atlantic
$50
Buy
35.35%
Upside
Initiated
03/31/25
BridgeBio initiated with a Buy at Redburn AtlanticBridgeBio initiated with a Buy at Redburn Atlantic
J.P. Morgan
$44→$50
Buy
35.35%
Upside
Reiterated
03/24/25
BridgeBio Pharma's Promising Market Position and Growth Potential in ATTR-CM and Beyond
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Mizuho Securities
Reiterated
05/02/25
Piper Sandler
Reiterated
04/30/25
Cantor Fitzgerald
Reiterated
04/29/25
Bank of America Securities
Reiterated
04/29/25
Leerink Partners
Reiterated
04/29/25
BMO Capital
$37
Hold
0.16%
Upside
Reiterated
04/29/25
Cautious Outlook for BridgeBio Pharma Amid Competitive Pressures and Market Uncertainties
H.C. Wainwright
$49→$53
Buy
43.48%
Upside
Reiterated
04/15/25
BridgeBio price target raised to $53 from $49 at H.C. WainwrightBridgeBio price target raised to $53 from $49 at H.C. Wainwright
Raymond James
$57
Buy
54.30%
Upside
Reiterated
04/01/25
Raymond James reiterates Outperform Rating on BridgeBio Pharma (BBIO)Raymond James analyst Danielle Brill reiterated an Outperform rating and $57.00 price target on BridgeBio Pharma (NASDAQ: BBIO).
Josh Smith CFA
Not Ranked
Redburn Atlantic
$50
Buy
35.35%
Upside
Initiated
03/31/25
BridgeBio initiated with a Buy at Redburn AtlanticBridgeBio initiated with a Buy at Redburn Atlantic
J.P. Morgan
$44→$50
Buy
35.35%
Upside
Reiterated
03/24/25
BridgeBio Pharma's Promising Market Position and Growth Potential in ATTR-CM and Beyond
Best Analysts Covering BridgeBio Pharma
Which Analyst Should I Follow If I Want to Buy BBIO and Sell After:
1 Month
xxx
Success Rate
11/21 ratings generated profit
Average Return
+10.95%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 52.38% of your transactions generating a profit, with an average return of +10.95% per trade.
3 Months
xxx
Success Rate
12/21 ratings generated profit
Average Return
+9.71%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +9.71% per trade.
1 Year
Success Rate
16/18 ratings generated profit
Average Return
+33.45%
reiterated a buy rating 3 days ago
Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +33.45% per trade.
2 Years
xxx
Success Rate
19/20 ratings generated profit
Average Return
+81.46%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 95.00% of your transactions generating a profit, with an average return of +81.46% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
BBIO Analyst Recommendation Trends
Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
20
10
10
16
14
Buy
14
20
27
26
15
Hold
5
2
2
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
39
32
39
43
30
Each month's total comprises the sum of three months' worth of ratings.
BBIO Financial Forecast
BBIO Stock Forecast FAQ
What is BBIO’s average 12-month price target, according to analysts?
Based on analyst ratings, BridgeBio Pharma Inc’s 12-month average price target is 58.81.
What is BBIO’s upside potential, based on the analysts’ average price target?
BridgeBio Pharma Inc has 59.20% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BBIO a Buy, Sell or Hold?
BridgeBio Pharma Inc has a consensus rating of Strong Buy which is based on 15 buy ratings, 1 hold ratings and 0 sell ratings.
What is BridgeBio Pharma Inc’s price target?
The average price target for BridgeBio Pharma Inc is 58.81. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $95.00 ,the lowest forecast is $37.00. The average price target represents 59.20% Increase from the current price of $36.94.
The highest analyst price target is $95.00 ,the lowest forecast is $37.00. The average price target represents 59.20% Increase from the current price of $36.94.
What do analysts say about BridgeBio Pharma Inc?
BridgeBio Pharma Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.
How can I buy shares of BBIO?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.